Abstract. We focused on the therapeutic effect of the stable gastric pentadecapeptide BPC 157 and how its action is related to nitric oxide (NO) in persistent colocutaneous fistula in rats (at 5 cm from anus, colon defect of 5 mm, skin defect of 5 mm); this peptide has been shown to be safe in clinical trials for inflammatory bowel disease (PL14736) and safe for intestinal anstomosis therapy. BPC 157 (10 μg / kg, 10 ng / kg) was applied i) in drinking water until the animals were sacrificed at post-operative day 1, 3, 5, 7, 14, 21, and 28; or ii) once daily intraperitoneally (first application 30 min following surgery, last 24 h before sacrifice) alone or with N G -nitro-L-arginine methyl ester (L-NAME) (5 mg / kg), L-arginine (200 mg/ kg), and their combinations. Sulphasalazine (50 mg / kg) and 6-α-methylprednisolone (1 mg / kg) were given once daily intraperitoneally. BPC 157 accelerated parenterally or perorally the healing of colonic and skin defect, leading to the suitable closure of the fistula, macro / microscopically, biomechanically, and functionally (larger water volume sustained without fistula leaking). L-NAME aggravated the healing failure of colocutaneous fistulas, skin, and colon wounds (L-NAME groups). L-Arginine was effective only with blunted NO generation (L-NAME + L-arginine groups) but not without (L-arginine groups). All of the BPC 157 beneficial effects remained unchanged with blunted NO-generation (L-NAME + BPC 157 groups) and with NO substrate (L-arginine + BPC 157 groups) as well as L-NAME and L-arginine co-administration (L-NAME + L-arginine + BPC 157 groups). Sulphasalazine was only moderately effective, and corticosteroid even had an aggravating effect.
Introduction
This study investigated the therapeutic approach to treat colocutaneous fistula. Of note, colocutaneous fistula is an anomalous connection between the skin and colon that provides the direct contact of these different, normally separated tissues, and thereby it presents special new circumstances and healing difficulties. As regular healing failure, it is present in diseases, such as diverticular disease, Crohn's disease, and colon malignancies, or recovery from surgery (1). An appropriate closing of the fistula, colocutaneous fistula pharmacotherapy, and solution of special underlying pathology could be not realized easily.
However, the success of the colocutaneous fistula pharmacotherapy, the healing of the colon defect, and healing of the skin defect to close fistulas may be interesting; and this could envisage a solution to the special underlying pathology of the fistulas. Basically, fistula closing should correlate with the agents' potency to (simultaneously) induce the healing of the skin and colonic wounds. Surprisingly, these were not investigated in experimental studies.
Thereby, in this study, we focused on the effect of the gastric pentadecapeptide BPC 157 on colocutaneous fistulas in rats. As an anti-ulcer peptide (2 -7) that also improves skin and healing of other types of wounds (8 -11) including transected muscle (12) and in particular the intestinal anastomosis in rats (13, 14) , BPC 157 was shown as safe in trials for inflammatory bowel disease (PL14736; Pliva, Croatia) (15, 16) . Additionally, BPC 157 interacts with nitric oxide (NO) (4, 17 -19) , and NO is commonly proposed to have an important role in wound healing (20) . Interestingly, studies with colocutaneous fistula as the model of a complex healing failure with NO-precursor and / or competitive inhibitor of nitric oxide synthase (NOS) application are still lacking and need to be performed.
This approach in the healing of the colocutaneous fistulas could be particularly interesting with respect to the BPC 157 therapy of inflammatory bowel disease (15, 16) . Namely, the visceral and skin wound healing is thought not to be comparable (21) . Also, the reported effects of NO-agents do not completely support such role of the NO-system (22 -25) . NO-agents, N G -nitro-Larginine methyl ester (L-NAME), a competitive NOSinhibitor, and L-arginine, a substrate for NOS, have discordant effects on skin and colon wound healing. In skin wounds, L-NAME impaired wound healing (22) , but increased wound collagen content, and decreased edema formation (23) , L-arginine decreased wound collagen (23) . In colon wounds, L-NAME improved (24) or suppressed (25) colocolonic anastomosis healing. Finally, since the 1980's the peptide growth factors were commonly supposed to be involved in the healing of the skin lesion and in the therapy of the colon lesion (for a review, see ref. 26 ). However, the simultaneous healing of these lesions or colocutaneous fistulas by the standard peptide growth factors remains to be demonstrated. Also, the peptide growth factors were not investigated under the background of blunted NOgeneration and NO-substrate presentation, that is, with L-NAME and L-arginine, given alone or in combination.
On the other hand, the stable gastric pentadecapeptide BPC 157 (2 -19) could have a particular relevance in colocutaneous fistula healing. Given in the same dose range, it ameliorated the skin (8 -11) and visceral (13, 14) wound healing [recently improved ileoileal anastomosis healing (13) , as previously colon-colon anastomosis healing (14) ]. Its strong anti-ulcer activity in the whole gastrointestinal tract (2 -9, 27, 28) led to its application in inflammatory bowel disease therapy, with no toxic effect, negative limit test, lethal dose (LD1) not achieved, and no side effects in trials (15, 16) .
Likely, a very safe peptide profile may be advantageous for colocutaneous fistula therapy (i.e., other agents for inflammatory bowel disease therapy showed remarkable side effects). Furthermore, it is stable in human gastric juice (29) [i.e., it has also been recently suggested to play an important physiological role and thereby recently reviewed (30, 31) ]; and it can be used without a carrier, unlike other peptides (for reviews, see refs. 32 and 33). In addition, very recently (34) , experiments demonstrated that recombinant human plateletderived growth factor homodimer of B-chains (PDGF-BB) and BPC 157 had similar selectivity for stimulation of granulation tissue in both sponge granuloma and in healing wounds. However, BPC 157 was more active in stimulating early collagen organization. It also stimulated expression of the early growth response 1 (egr-1) gene and its repressor nerve growth factor 1-A-binding protein-2 (nab2) more rapidly than PDGF-BB. EGR-1 induces cytokine and growth factor generation and early extracellular matrix (collagen) formation, offering an explanation for the beneficial effects of BPC 157 on wound healing (34) , likely relevant for colocutaneous fistula healing as well. In addition, this peptide is more effective than standard treatments in the healing of ulcers (2, 5 -7, 27, 28) and various other types of wound healing (8 -14, 34 -36) , both locally and systemically (perorally, parenterally).
All together, we suggest BPC 157's beneficial activity on the special healing circumstances in the colocutaneous fistulas healing as well. Thus, we studied gastric pentadecapeptide BPC 157 parenteral and peroral therapy in rats with colocutaneous fistulas. For comparison, we used sulphasalazine and 6-α-methylprednisolone [given in the doses previously demonstrated to counteract colitis induced by cysteamine enema (27, 28) ], as the standard therapy of inflammatory bowel disease (27, 28) . Interestingly, although the therapies used for pyoderma gangrenosum also include systemic corticosteroids and sulphasalazine (37) , the specific sulphasalazine studies on skin wound healing are lacking while 6-α-methylprednisolone suppressed spontaneous healing of open wounds (38) . L-NAME, and thereby, blunted generation of NO, and L-arginine as NO-substrate (39, 40) [given in the doses previously demonstrated to interact with BPC 157 (4, 17 -19) ], were applied, alone or in combination with BPC 157. This regimen was usefully given in our previous in vivo / in vitro studies (4, 17 -19) , and it could be more relevant than the usual limitation to blunted generation of NO only (for a review, see ref. 4) since agents that liberate NO could 3.5 ± 0.5* 6.1 ± 0.9* 3.5 ± 0.6* 1.3 ± 0.3 BPC, 10 ng /kg, i.p.
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Materials and Methods
We used male Albino Wistar rats, 250 -280 g body weight, kept under normal conditions, 10 rats at least per each experimental group and period, randomly assigned for all of the experiments, approved by our Local Ethics Committee.
In anaesthetized rats, we created the colocutaneous fistula at 5 cm from the anus, colon defect of 5 mm, skin defect of 5 mm. The rats received pentadecapeptide BPC 157 [without carrier or peptidase inhibitor, manufactured by Diagen, Ljubljana, Slovenia (2 -4, 6 -9, 12 -14, 17 -19, 27, 28, 35, 36, 42, 43) , GEPPPGKPADDAGLV, M.W. 1419, dissolved in saline] (0.16 μg/ ml) or nothing in the drinking water (12.0 ml / rat) until the sacrifice or once daily, intraperitoneally BPC 157 10.0 μg / kg, 10.0 ng / kg, or saline (5.0 ml / kg b.w.), first application at 30 min after surgery, final 24 h before sacrifice. Alternatively, sulphasalazine (Sigma, St. Louis, MO, USA) (50 mg / kg intraperitoneally, once daily) or 6-α-methylprednisolone (Sigma) (1.0 mg / kg intraperitoneally, once daily) [as described before in colitis-studies (27, 28) ] were given. Finally, as described previously (4, 17 -19), BPC 157 (10.0 µg/kg) or L-NAME (5.0 mg/kg), L-arginine (200.0 mg / kg), and D-arginine (200.0 mg / kg) (Sigma) were given intraperitoneally alone or in combination (Darginine was not effective, data not shown).
Immediately after the sacrifice at post-operative day 1, 3, 5, 7, 14, 21, and 28, the skin and colon defects were assessed as described before (2 -4, 6 -9, 12 -14, 17 -19, 27, 28, 35, 36, 42, 43) . Briefly, the largest diameter of the skin or colon defect (considering funnel presentation of the colonic defect in rats with colocutaneous fistula, the two diameters were assessed, the inner at the fistula's orifice and the outer at the defect surface) was assessed (mm) and then the tissue processed for further microscopic analysis (2 -4, 6 -9, 12 -14, 17 -19, 27, 28, 35, 36) . Using the previously used method (13) , in a separate group of animals, the fistula leakage and the closure of the fistula were assessed by studying the volume (mL) that was sustained before the initiation of the leakage through the fistula. The volume of saline was infused through a syringe-perfusion pump system (Argus 600; Argus Medical A6, Heimberg, Switzerland) at the rate of 1 mL / 10 s. The infusion was stopped at the point when the leakage through the external aperture of the fistula started. If not leaking till the end of the fifth minute, the fistula was considered to be functionally closed.
Statistical analysis of the quantified data was performed by ANOVA. Post-hoc comparisons were appraised using the conservative Bonferroni / Dunn test. Data are each presented as the mean ± S.D. Values of P<0.05 were considered statistically significant.
Results
In general, the control rats defecated through the fistula, their colucoutaneous fistulas exhibited very poor healing, without spontaneous healing and fistula closure throughout the 28-day post-healing period (Tables 1 and  2 and Figs. 1 and 2) . The skin defect remained open. Also, the colon defect remained apparent. Water volume that was sustained without fistula leaking remained continuously low. Besides, a further complication in the healing course of the colocutaneous fistulas showed an additional aggravation: with an additional rise, the colon and skin defects override their initial size. Microscopically, the fistula wall is built partially of colon and partially of skin tissue separated by an area of granulation tissue, covered by fibrin and permeated by granulocytes. In deeper portions, some mononuclear cells are present. After 14 days, less fibrin and more granulation tissue is present.
This was improved by sulphasalazine and to a much higher extent by pentadecapeptide BPC 157 application, μg-and ng-regimens, either parenteral or peroral. On Skin defect, colonic defect (outer diameter at the defect surface, inner diameter at the fistula's orifice), volume sustained before the initiation of the leakage through the fistula, mean ± S.D. *P<0.05 vs corresponding control (i.e., saline). After colocutaneous fistula creation, the rats received medication [pentadecapeptide BPC 157 dissolved in saline (10 μg/ kg), L-NAME (5 mg/kg) and L-arginine (200 mg/kg), or saline (5.0 ml/kg), intraperitoneally, alone or in combination, first application at 30 min after surgery, final 24 h before sacrifice]. Ten rats at least per each of the experimental groups. Fig. 1 . Characteristic presentation of the colon defect in rats with colocutaneous fistula at post-operative day 3 (3d), 7 (7d), 21 (21d), and 28 (28d) in controls (C) and 6-α-methylprednisolone (1 mg /kg, i.p., once daily) (MP)-, sulphasalazine (50 mg /kg, i.p., once daily) (S)-, and gastric pentadecapeptide BPC 157 (10 μg/kg, i.p., once daily) (B)-treated rats. Normally, colucoutaneous fistulas exhibited very poor healing, without spontaneous healing throughout the 28-day post-healing period in the controls (3d-C, 7d-C, 21d-C, 28d-C). Therapeutic effects of the gastric pentadecapeptide BPC 157 on the healing of both colonic and skin defect led to the suitable closure of the fistula at the end of the 28-day experimental period (3d-B, 7d-B, 21d-B, 28d-B). Sulphasalazine showed a moderate effect only (3d-S, 7d-S, 21d-S, 28d-S), and 6-α-methylprednisolone showed an opposite, aggravating effect (3d-MP, 7d-MP, 21d-MP, 28d-MP).
Fig. 2.
Characteristic presentation of the skin defect in rats with colocutaneous fistula at post-operative day 28 (28d) in controls (C) and 6-α-methylprednisolone (1 mg/kg, i.p., once daily) (MP)-, sulphasalazine (50 mg /kg, i.p., once daily) (S)-, gastric pentadecapeptide BPC 157 (10 µg /kg, i.p., once daily) (B)-treated rats. Normally, colucoutaneous fistulas exhibited very poor healing, without spontaneous healing throughout the 28-day posthealing period in the controls (28d-C). Therapeutic effects of the gastric pentadecapeptide BPC 157 on the healing of both colonic and skin defect led to the suitable closure of the fistula at the end of the 28-day experimental period (28d-B). Sulphasalazine showed a moderate effect only (28d-S), and 6-α-methylprednisolone showed an opposite, aggravating effect (28d-MP).
the other hand, 6-α-methylprednisolone could even aggravate the natural poor healing course (Table 1 and Figs. 1 and 2). As could be seen since the very early post-operative period (3 -5 days) in pentadecapeptide BPC 157 rats (both parenteral and peroral regimens), the colocutaneous fistula healing is considerably improved, grossly (closure of both skin and colon defect), biomechanically, and functionally (larger water volume that could be sustained without fistula leaking). These were along with the lack of a large necrotic area of superficial epithelium and broad band of necrotic subcutaneous tissue and muscle otherwise noted in the controls. Later, walled with granulation tissue in controls, fistulous channel was replenished in BPC 157 rats (poor granulation tissue formation, prominent regeneration of subcutaneous muscle fibers). Contrary to the improvement in pentadecapeptide BPC 157 rats seen from the early period, sulphasalazine improved the healing not before the latter period (21 -28 post-operative days). Interestingly, the aggravation induced by 6-α-methylprednisolone has been also exhibited at that latter period.
Our data support that since the very early period, there was a downhill course related to the blunted NOgeneration with L-NAME, showing that L-NAME alone further aggravated (i.e., fistula, skin, and colon wounds healing) (L-NAME groups) while L-arginine counteracted L-NAME-aggravation of the control values (L-NAME + L-arginine groups). However, the levels observed with L-arginine given alone remained within the control values of the healing course of colocutaneous fistula, skin wound, and colon wound (L-arginine groups). Also, L-NAME-blunted NO-generation (L-NAME + BPC 157 groups) and NO substrate presentation (L-arginine + BPC 157 groups); these results demonstrated the pertinent efficiency of the all of BPC 157 healing effects (colocutaneous fistula, skin wound, and colon wound). More than L-arginine, BPC 157 completely counteracted L-NAME effects (L-NAME + BPC 157 groups and L-NAME + L-arginine + BPC 157 groups) and fully reestablished all of the healing effects. However, BPC 157 beneficial effects could be not further augmented when BPC 157 was co-administered with L-arginine (L-arginine + BPC 157 groups) ( Table 2 ).
Discussion
The examinations of the rats with unhealed colocutaneous fistulas may highlight not only the problem of colocutaneous fistulas, but also the healing of skin and colon wounds and the therapy of colocutaneous fistulas, skin, and colon wounds healing. We found that the healing rate of the persistent colocutaneous fistulas, skin, and colon wounds were not different. We evidenced closely inter-related processes, related to the NO-system and therapy-dependent. They could be improved (BPC 157, sulphasalazine), speedily and prominently (BPC 157), or slowly with delay and only modestly (sulphasalazine). Alternatively, they could be aggravated, rapidly and prominently (L-NAME) or slowly with delay and moderately (6-α-methylprednisolone). Only pentadecapeptide BPC 157 induced suitable closure of the fistula at the end of the 28-day experimental period and considerable improvement starting already during the very early post-operative period. So, we suggested that there was a relationship between BPC 157, the NO system, and the healing of colocutaneous fistuals and skin and colon wounds.
Methodologically, the evidence obtained with combined multiple parameters in fistula rats could resolve the problems found in previous studies investigating the effect of other agents on skin and colon wound healing since those studies investigated only one parameter (22 -25, 37) , either only skin wound (22, 23, 37) or only colon wound (24, 25) . Namely, the rats' colocutaneous fistulas exhibited a particular "self-controlling model system" (i.e., the healing of the skin defect -the healing of the colon defect and fistula closure). On the other hand, this can firmly substantiate the healing onset, extent, and rate that could be achieved with a particular agent. Tested drugs (BPC 157, sulphasalazine, 6-α-methylprednisolone, L-NAME) really may have either a beneficial or worsening effect on both colonic and cutaneous wounds. Alternatively, the improvement or aggravation of healing may be either for the colon or skin wound (that was however not found). Finally, there may be neither improvement nor aggravation of healing (L-arginine). Thereby, the tested agents (BPC 157, sulphasalazine, 6-α-methylprednisolone, L-NAME) may exhibit so-called parallel healing actions when the onset of the healing of colon and skin wound simultaneously appeared. Alternatively, if the onset of the healing of these wounds was different (that was however not found), then the tested agents may exhibit non-parallel healing actions. Thus, these findings mean that parenteral or peroral applications of BPC 157 should be responsible for successfully counteracting the regular healing failure, and the colocutaneous fistula, skin, and colon wounds healing markedly improved.
The healing colocutaneous fistula -skin and colon wounds -NO-system relation was largely undetermined. However, we suggested that the observed improvements made by pentadecapeptide BPC 157 in rats with colocutaneous fistula may be related to the NO-system. Also, we proposed that the NO-system has a particular significance in this multiple wound healing system: maintaining an undisturbed and non-blunted NO-generation would sustain the normal healing course of the colocutaneous fistula, skin, and colon wounds. As indicated before, using the same L-NAME / L-arginine protocol (4, 17 -19), L-NAME and blunted NO-generation may induce a further healing failure (L-NAME goups). L-Arginine application (NO-substrate presentation) was alone inefficient (L-arginine group), but in combination, it counteracted L-NAME-effects to the control level (L-NAME + L-arginine groups). However, it should be noted that NO functions as an endogenous wound healing factor (20) , implying a possible further improvement over control values along with a suitable counteraction of blunted NO-generation and a clear amelioration of the healing induced by the given agent (20) . On the contrary, L-arginine was effective only with (but not without) blunted NO-generation (L-arginine groups). These likely suggest that L-arginine as an endogenous wound healing improvement factor would not be able to reproduce efficiently supposed NO beneficial functions (20) . On the other hand, BPC 157 completely counteracted L-NAME effects (L-NAME + BPC 157 groups and L-NAME + L-arginine + BPC 157 groups) and fully reestablished all of the healing effects. These parallels that rapidly emerge to restore homeostasis seemed to be fully present since the very early period until the end of the experimental.
These effects of BPC 157 that are promptly initiated and then sustained should be viewed accordingly with its previous healing effects on skin (8 -11) and visceral (13, 14) wounds and the BPC 157 -NO-relation based on a complex interaction with L-NAME and L-arginine regimen evidenced in previous studies (4, 17 -19) . This may be important to define the commonly supposed significance of the NO-system in wound healing and healing improvement by administration of a particular agent (20) . On the contrary, postponed presentation characterized the beneficial effect of sulphasalazine and healing aggravation of 6-α-methylprednisolone that appeared at the latter period.
Such an effect of BPC 157 on NO-system function (L-NAME-counteracted) or a parallel effect (note, Larginine did not augment BPC 157's beneficial effect) can be obviously needed. The otherwise incurable anomalous connection between the skin and colon and anomalous interactions between these different normally separated tissues were redirected toward the healed colonic defect and healed skin defect seen in all pentadecapeptide BPC 157-treated rats. Thereby, they exhibited a better organized healing process that may be simultaneously relevant for both skin (8 -11) and colon (13, 14) wound healing. Accordingly, as noted previously in skin (8, 9) and visceral (13, 14) wounds, throughout the complete post-operative period, these findings were also supported biomechanically and functionally. Larger water volume that could be sustained without fistula leaking was consistently noted in BPC 157 groups. Supportingly, parenteral and peroral application of the peptide had similar efficiency, like in previous studies (for reviews, see refs. 2 -4, 6 -9, 12 -14, 17 -19, 27, 28, 35, 36, 42, 43) . Likewise, this peptide is stable in human gastric juice (more for 24 h) (29) and recognized to be a basal protectant in the saliva and gastric juice (30, 31, 42, 43) . Thereby, it could be that the commonly suggested peptide growth factor involvement in the healing of the skin and colon lesion (26) may be practically proved with BPC 157's application. This practical demonstration may be indicative since the standard peptide growth factors are rapidly degraded [i.e., h-EGF and h-TGF in human gastric juice (29)], and their therapeutic potential had not been demonstrated in complex fistulous conditions (26) .
Fistulas generally indicate an underlying active disease [for review see, i.e., (13) ]. This should be pointed out with respect to the improved healing of colocutaneous fistula, skin, and colon wounds and the suggested use of pentadecapeptide BPC 157 in inflammatory bowel disease therapy; when BPC 157 was used previously, LD1 could be not achieved, limit test negative, no side effects were found in trials, and no complications were observed (15, 16) .
Consequently, these fistulas may respond to such therapy aimed at the underlying inflammatory process (for review, see ref. 13 ). Importantly, pentadecapeptide BPC 157's beneficial effect on both the wound and mucosa healing reduces the number of inflammatory cells (8, 9, 44) and levels of leukotriene B 4 (LTB 4 ), thromboxane B 2 (TXB 2 ), and myeloperoxidase (MPO) in the serum and inflamed tissues (45, 46) . Together, these could significantly affect the afferent nerve function (47) . As seen in capsaicin studies, pentadecapeptide BPC 157 interacts with and restores the somatosensory neurons system function, in both the adult and new-born rats (3). It improves the sciatic nerve healing following anastomosis (48) . Finally, these could be combined with the noted BPC 157 effect on the NO-system and colocutaneous fistula healing, presenting the essential role of NO in collagen tissue organization (20) and mucosa integrity maintenance (39) , as in wound healing (20) . Indeed, the BPC 157 / NO-relation was previously consistently seen both in vivo and in vitro [in the gastric mucosa (4, 17)]. BPC 157 might modulate (and / or induce) NO-synthesis in different species (4, 17 -19) . Likewise, BPC 157 might affect both NO-agonist and NOS-blocker (4, 17 -19) . Based on the close similarity of the determination of NO-synthesis in gastric and other tissues (39) , this pentadecapeptide would probably have a similar activity in other organs as well, which is relevant for both the skin and mucosa healing. In support of this, BPC 157 has a strong angiogenic effect (12, 35, 49) [i.e., angiogenesis is an essential component of ulcer healing since it assures delivery of oxygen and nutrients to the healing site (26) ]. Likewise, BPC 157 counteracted endothelin over-expression (50) . It is notable that a better collagen organization was consistently seen with the use of pentadecapeptide BPC 157 (8 -14, 34 -36, 51, 52 ). This clearly corresponds to prominently stimulated expression of egr-1 gene, which induces cytokine and growth factor generation and early extracellular matrix (collagen) formation, and its repressor nab2 by pentadecapeptide BPC 157 (34) .
Finally, pentadecapeptide BPC 157, efficient in therapy of the inflammatory bowel disease (PL14736) (15, 16) and intestinal anastomosis healing (13, 14) , counteracted the colitis induced by a variety of ulcerogens such as cysteamine (27, 28) , trinitrobenzene sulfonic acid (TNBS) (45, 46) , iodoacetamide (53) . Obviously, all these findings may also help to explain the improvement of colocutaneous fistula healing by BPC 157.
Thus, it seems likely that other mechanisms should be also implicated in superior BPC 157 efficiency. The effects of BPC 157 in therapy of fistulous conditions overrides the onset, extent, and rate of healing seen with sulphasalazine (this study, however, provided the first demonstration of the effect of sulphasalazine on skin wound healing, although delayed). Also, the effects of BPC 157 are opposite to the aggravation induced by 6-α-methylprednisolone. Furthermore, the corticosteroid systemic administration is known to generally impair the healing and to adversely affect wound healing in various experimental models involving the skin and other tissues (20, 52, 54) . In support of this, the incidence of fistulas is highly increased in the corticosteroidresistant inflammatory bowel disease patients (55) . Interestingly, pentadecapeptide BPC 157 counteracted corticosteroid-induced impairment of burn healing (9) and some other types of tissue healing (52) . Also, it inhibited corticosteroid-induced immunosuppression (9) .
Finally, pentadecapeptide BPC 157-treated rats with colocutaneous fistulas generally exhibited improved breaking strength. Of note, the breaking strength of the fistula is regularly thought to be a direct reflection of the successful repair process (13, 14, 56) . The increase of breaking strength essentially exemplifies the advanced healing process and shows the efficiency of the applied therapy (13, 14, 56) . Namely, colocutaneous fistulas spontaneously heal unless complicated (1). Here, the controls exhibited the persistent fistulas, which showed constant biomechanical and functional (i.e., significant leaking of the fistulas) deficits. Thus, these rats with colocutaneous fistulas bear a constant and complicated healing failure that was rapidly counteracted by pentadecapeptide BPC 157. With the standard agents, these complicated persistent fistulas could be hardly corrected even with long-term therapy [i.e., modest efficiency of the sulphasalazine and an opposite aggravation (i.e., increased fistulas leaking) in 6-α-methylprednisolone groups)].
In conclusion, successful therapeutic effects of the pentadecapeptide BPC 157 in rats with fistulas are important. Particularly, an aggravation related to blunted NO-generation was completely counteracted (4, 17 -19) . The prominent anti-ulcer (2 -9, 27, 28, 31, 42 -46) and wound-healing effect (8 -14, 34 -36, 48, 51, 52) resolved complicated persistent fistula healing and exhibited a relationship with the NO-system. These healing activities on both colonic and skin defects leading to the fistula closure further revealed the significance of gastric pentadecapeptide BPC 157. Besides, the occurrence of myocytes contraction is essential for an appropriate wound closure (57) . Possibly, the most recently demonstrated beneficial effects on injured muscle (6, 7, 12, 13) and muscle healing of the striated (12) and smooth muscle (6, 7, 13) could also contribute to the fistula closing using BPC 157 application. Finally, it is effective without a carrier (2 -14, 17 -19, 27, 28, 31, 34 -36, 42 -46, 48 -52) . In contrast, other peptides that require the use of a peptide + carrier(s)-complex present considerable methodological / activity dilemmas (32, 33) . In addition, BPC 157 is already proved to be effective in trials for inflammatory bowel therapy (PL14736) (15, 16) . Thus, this study gives encouraging evidence, providing an advantageous background for the further therapeutic attempts with BPC 157 administration. 
